Overview
Pediatric Sarcomas: Sarcomas are among the most difficult-to-treat cancers in pediatric oncology, with metastatic forms having the highest mortality. We have established genetically defined human cell-based models and genetically engineered murine models for the pediatric skeletal muscle cancer known as rhabdomyosarcoma. Using these models, we can study the causative role of certain genetic changes (e.g. chromosomal translocations and oncogenic RAS) in rhabdomyosarcoma formation and treatment resistance. Specific goals of this research program include the identification of signaling pathways corrupted in rhabdomyosarcoma, with focus on the PAX3::FOXO1 mutation and its downstream effectors and oncogenic RAS, and identification of new therapeutic targets for treatment of this childhood cancer.
Current Duke Appointments & Affiliations
Associate Professor of Pediatrics
·
2012 - Present
Pediatrics, Hematology-Oncology,
Pediatrics
Associate Professor of Pharmacology and Cancer Biology
·
2012 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Associate Professor of Cell Biology
·
2022 - Present
Cell Biology,
Basic Science Departments
Member of the Duke Cancer Institute
·
1999 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.
Journal article Br J Cancer · June 13, 2026 The third in a series of Paediatric Therapeutic Development Workshops focused on rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sarcoma in children, with 90% survival for those with the lowest risk disease, but just 20-30% in children wi ... Full text Link to item CiteFusion-positive rhabdomyosarcoma oncofusions share a common interactome.
Journal article Nat Commun · May 28, 2026 Fusion-positive rhabdomyosarcoma (FP-RMS) arises from at least seven distinct oncofusions sharing a common PAX3/7 N-terminal DNA-binding domain fused to divergent C-terminal partners. How different oncofusions produce the same cancer was unknown. Here we s ... Full text Link to item CiteAbstract 1155: High-throughput screening identifies synergistic drug interactions between CDK8/19 and DHFR inhibitors in rhabdomyosarcoma
Conference Cancer Research · April 3, 2026 AbstractRhabdomyosarcoma (RMS) is an aggressive pediatric soft-tissue sarcoma marked by substantial treatment-related morbidity and poor outcomes, particularly in metastatic or recurrent disease. Although ... Full text CiteRecent Grants
Cell and Molecular Biology Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institute of General Medical Sciences · 2026 - 2031Identification and targeting of essential regions of driver fusion oncoproteins in rhabdomyosarcoma
ResearchPrincipal Investigator · Awarded by V Foundation for Cancer Research · 2025 - 2030Pharmacological Sciences Training Program
Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030View All Grants
Education
Duke University ·
1995
M.D.
Duke University ·
1993
Ph.D.